(Duligotuzumab)Biosimilar Reference Antibody-GS40196 新品

货号：GS40196

Duligotuzumab (also known as MEHD7945A) is an investigational bispecific human monoclonal antibody that was developed as a targeted therapy for cancer. It is engineered to simultaneously inhibit two key members of the epidermal growth factor receptor (EGFR/HER) family: EGFR (HER1) and HER3. By blocking signaling from both receptors, the drug aimed to overcome resistance mechanisms seen with single-target EGFR inhibitors. Clinical trials evaluated its efficacy, primarily in combination with chemotherapy, for the treatment of advanced solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC). However, its development was discontinued after it failed to demonstrate superior efficacy compared to standard EGFR-targeted therapies (e.g., cetuximab) in randomized phase II trials.